Clinical trial Recruiting at 3 sites Observational Ages 18 to 75

Analysis of large-cell lung cancer and its metastasis

Official title: Integrative Analysis of Large-cell Lung Carcinoma

Run by Shanghai 10th People's Hospital · NCT02917369 · Data updated 2026-11-12

This study is trying to understand large-cell lung cancer and how it spreads by comparing normal lung tissue to cancer samples, including those that have spread to the liver.

More Lung Cancer trials

Quick facts

Study typeObservational
Ages18 Years to 75 Years
SexAll
Enrollment1000 (estimated)
SponsorShanghai 10th People's Hospital
Academic / other
Drugs / interventionschemotherapy
Locations3 sites (Ganzhou, Jiangxi and 2 other locations)
StatusRecruiting
StartedJanuary 2016
Main results expectedDecember 2026
Study endsDecember 2026
Registry record updatedSeptember 28, 2016
Trial IDNCT02917369 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients aged 75 years or younger with histologically confirmed large-cell lung cancer and a WHO performance status of 0 or 1.

Probably not a fit

Patients over the age of 75, those with severe major organ dysfunction, or those who have received prior cancer chemotherapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study conducts an integrative analysis of large-cell lung cancer (LCLC) by examining the proteomes of paired normal lung tissues and LCLC samples, both with and without liver metastasis. The methodology includes sequencing transcriptomes, whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets of normal lung tissue, primary LCLC carcinoma, and its matched metastasis. Additionally, the study will analyze genomic data from lung cancer previously characterized by The Cancer Genome Atlas (TCGA) to perform integrated proteogenomic analyses.

Why it matters

Potential benefit: If successful, this study could enhance understanding of LCLC and its metastasis, potentially leading to improved treatment strategies.

How similar studies have gone: Other studies utilizing integrative analyses of cancer genomics have shown promise, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≤ 75 years with histologically proven LCLC
* No severe major organ dysfunction
* World Health Organization (WHO) performance status of 0 or 1
* No prior cancer chemotherapy

Exclusion Criteria:

* Age ≥ 76
* Severe major organ dysfunction
* WHO performance status of \>1
* Prior cancer chemotherapy

Where it's running

  • Ganzhou City People's Hospital
    Ganzhou, Jiangxi, China
    Recruiting
  • Shanghai Tenth People's Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.